These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 19845762)

  • 1. Complementary medicinal chemistry-driven strategies toward new antitrypanosomal and antileishmanial lead drug candidates.
    Cavalli A; Lizzi F; Bongarzone S; Belluti F; Piazzi L; Bolognesi ML
    FEMS Immunol Med Microbiol; 2010 Feb; 58(1):51-60. PubMed ID: 19845762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parasitology. Drugs to combat tropical protozoan parasites.
    Gelb MH; Hol WG
    Science; 2002 Jul; 297(5580):343-4. PubMed ID: 12130767
    [No Abstract]   [Full Text] [Related]  

  • 3. SAR studies on azasterols as potential anti-trypanosomal and anti-leishmanial agents.
    Gigante F; Kaiser M; Brun R; Gilbert IH
    Bioorg Med Chem; 2009 Aug; 17(16):5950-61. PubMed ID: 19620005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diamidines as antitrypanosomal, antileishmanial and antimalarial agents.
    Werbovetz K
    Curr Opin Investig Drugs; 2006 Feb; 7(2):147-57. PubMed ID: 16499285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metal-based drugs for malaria, trypanosomiasis and leishmaniasis: recent achievements and perspectives.
    Navarro M; Gabbiani C; Messori L; Gambino D
    Drug Discov Today; 2010 Dec; 15(23-24):1070-8. PubMed ID: 20974285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenothiazine inhibitors of trypanothione reductase as potential antitrypanosomal and antileishmanial drugs.
    Chan C; Yin H; Garforth J; McKie JH; Jaouhari R; Speers P; Douglas KT; Rock PJ; Yardley V; Croft SL; Fairlamb AH
    J Med Chem; 1998 Jan; 41(2):148-56. PubMed ID: 9457238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptoid inhibition of trypanothione reductase as a potential antitrypanosomal and antileishmanial drug lead.
    Chan C; Yin H; McKie JH; Fairlamb AH; Douglas KT
    Amino Acids; 2002 Jun; 22(4):297-308. PubMed ID: 12107758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rational approaches for drug designing against leishmaniasis.
    Shukla AK; Singh BK; Patra S; Dubey VK
    Appl Biochem Biotechnol; 2010 Apr; 160(8):2208-18. PubMed ID: 19756413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-throughput screening platform for natural product-based drug discovery against 3 neglected tropical diseases: human African trypanosomiasis, leishmaniasis, and Chagas disease.
    Annang F; Pérez-Moreno G; García-Hernández R; Cordon-Obras C; Martín J; Tormo JR; Rodríguez L; de Pedro N; Gómez-Pérez V; Valente M; Reyes F; Genilloud O; Vicente F; Castanys S; Ruiz-Pérez LM; Navarro M; Gamarro F; González-Pacanowska D
    J Biomol Screen; 2015 Jan; 20(1):82-91. PubMed ID: 25332350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neglected tropical diseases: multi-target-directed ligands in the search for novel lead candidates against Trypanosoma and Leishmania.
    Cavalli A; Bolognesi ML
    J Med Chem; 2009 Dec; 52(23):7339-59. PubMed ID: 19606868
    [No Abstract]   [Full Text] [Related]  

  • 11. Natural products as trypanocidal, antileishmanial and antimalarial drugs.
    Fournet A; Muñoz V
    Curr Top Med Chem; 2002 Nov; 2(11):1215-37. PubMed ID: 12171582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-leishmanial drug discovery: rising to the challenges of a highly neglected disease.
    Sharlow ER; Grögl M; Johnson J; Lazo JS
    Mol Interv; 2010 Apr; 10(2):72-5. PubMed ID: 20368366
    [No Abstract]   [Full Text] [Related]  

  • 13. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and evaluation of 2,4-diaminoquinazolines as inhibitors of trypanosomal and leishmanial dihydrofolate reductase.
    Khabnadideh S; Pez D; Musso A; Brun R; Pérez LM; González-Pacanowska D; Gilbert IH
    Bioorg Med Chem; 2005 Apr; 13(7):2637-49. PubMed ID: 15755663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial peptides for leishmaniasis.
    Cobb SL; Denny PW
    Curr Opin Investig Drugs; 2010 Aug; 11(8):868-75. PubMed ID: 20721829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis of a small library of 2-phenoxy-1,4-naphthoquinone and 2-phenoxy-1,4-anthraquinone derivatives bearing anti-trypanosomal and anti-leishmanial activity.
    Bolognesi ML; Lizzi F; Perozzo R; Brun R; Cavalli A
    Bioorg Med Chem Lett; 2008 Apr; 18(7):2272-6. PubMed ID: 18353643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cysteine proteases as potential targets for anti-trypanosomatid drug discovery.
    Judice WAS; Ferraz LS; Lopes RM; Vianna LDS; Siqueira FDS; Di Iorio JF; Dalzoto LAM; Trujilho MNR; Santos TDR; Machado MFM; Rodrigues T
    Bioorg Med Chem; 2021 Sep; 46():116365. PubMed ID: 34419821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potentials of marine natural products against malaria, leishmaniasis, and trypanosomiasis parasites: a review of recent articles.
    Nweze JA; Mbaoji FN; Li YM; Yang LY; Huang SS; Chigor VN; Eze EA; Pan LX; Zhang T; Yang DF
    Infect Dis Poverty; 2021 Jan; 10(1):9. PubMed ID: 33482912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting atypical trypanosomatid DNA topoisomerase I.
    Balaña-Fouce R; Redondo CM; Pérez-Pertejo Y; Díaz-González R; Reguera RM
    Drug Discov Today; 2006 Aug; 11(15-16):733-40. PubMed ID: 16846801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The trypanothione system and the opportunities it offers to create drugs for the neglected kinetoplast diseases.
    Flohé L
    Biotechnol Adv; 2012; 30(1):294-301. PubMed ID: 21620942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.